Senaparib is a drug under investigation for the treatment of cancer. It is a PARP inhibitor. In January 2025, senaparib was approved for use in China for treatment of advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.